Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an undisclosed upfront ...
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...
Inflammatory bowel disease is a chronic condition of unknown origin characterized by severe inflammation and mucosal destruction in the intestine. There are two main forms: Crohn s disease, which can ...
Correspondence to Dr Christopher Andrew Lamb, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; christopher.lamb{at}newcastle.ac.uk and Dr A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback